A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 413 participants.

Also called NCT01392573

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 413 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01392573
  • EudraCT 2011-002336-72
Other papers using this trial's data
  • A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges Diabetes technology & therapeutics, 2017-04 DOI, PubMed 28282219, PMC5399738 In the PMC Open Access subset under CC BY-NC.
  • Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) Diabetes care, 2014-11 DOI, PubMed 25114296
  • EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2019-02 DOI, PubMed 30383495

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Bulgaria, Denmark, Hungary, India, Slovenia, Switzerland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01392573. Randomized; double masking; primary purpose treatment. Start 2011-11-28 (actual); primary completion 2012-10-01 (actual). Results posted on 2017-01-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes
Acronym
DUAL™ II
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
insulin degludec/liraglutide
Intervention (Drug)
insulin degludec
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01392573
Content hash
a026149c3de130bc7bb46b828886e20ba5367f658d17ae80c136f979608d251f